The Food and Drug Administration's Proposed Method for Adjusting Data on Antimicrobials Sold or Distributed for Use in Food-Producing Animals Using a Biomass Denominator; Availability, 38695-38696 [2017-17206]
Download as PDF
Federal Register / Vol. 82, No. 156 / Tuesday, August 15, 2017 / Notices
the terms as outlined in the FY 2017
Notice of Award for each program.
DATES: Funds will be realloted after
September 1, 2017 and before
September 30, 2017.
ADDRESSES: The reallotment amounts to
SCDDs and P&As can be found at
https://www.acl.gov/node/110.
FOR FURTHER INFORMATION CONTACT:
Andrew Morris, Office of Policy and
Development, Center on Policy &
Evaluation, Administration for
Community Living, 330 C St. SW.,
Washington, DC 20201. Telephone (202)
795–7408. Email andrew.morris@
acl.hhs.gov. Please note the telephone
number is not toll free. This document
will be made available in alternative
formats upon request. Written
correspondence can be sent to
Administration for Community Living,
U.S. Department of Health and Human
Services, 330 C St. SW., Washington, DC
20201.
Dated: August 4, 2017.
Melissa Ortiz,
Commissioner, Administration on
Disabilities.
[FR Doc. 2017–17195 Filed 8–14–17; 8:45 am]
BILLING CODE 4154–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2017–N–1197]
The Food and Drug Administration’s
Proposed Method for Adjusting Data
on Antimicrobials Sold or Distributed
for Use in Food-Producing Animals
Using a Biomass Denominator;
Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or Agency) is
announcing the availability for public
comment of a proposed method for
applying a food animal biomass
denominator to annual data on
antimicrobials sold and distributed for
use in food animals in the United States.
This method will allow us to obtain a
corrected estimate of antimicrobial drug
sales relative to the animal population
potentially being treated with those
drugs, thereby lending further context to
the antimicrobial sales data we are
collecting and analyzing.
DATES: Submit either electronic or
written comments on the proposed
method by November 13, 2017.
mstockstill on DSK30JT082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
21:43 Aug 14, 2017
Jkt 241001
You may submit comments
as follows. Please note that late,
untimely filed comments will not be
considered. Electronic comments must
be submitted on or before November 13,
2017. The https://www.regulations.gov
electronic filing system will accept
comments until midnight Eastern Time
at the end of November 13, 2017.
Comments received by mail/hand
delivery/courier (for written/paper
submissions) will be considered timely
if they are postmarked or the delivery
service acceptance receipt is on or
before that date.
ADDRESSES:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2017–N–1197 for ‘‘FDA’s Proposed
Method for Adjusting Data on
Antimicrobials Sold or Distributed for
Use in Food-Producing Animals Using a
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
38695
Biomass Denominator.’’ Received
comments, those filed in a timely
manner (see ADDRESSES), will be placed
in the docket and, except for those
submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://www.gpo.gov/
fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852.
Submit written requests for single
copies of the proposed method to the
Policy and Regulations Staff (HFV–6),
Center for Veterinary Medicine, Food
and Drug Administration, 7519 Standish
Pl., Rockville, MD 20855. Send one selfaddressed adhesive label to assist that
office in processing your requests.
Persons with access to the Internet may
obtain the proposed method at either
https://www.fda.gov/ForIndustry/User
Fees/AnimalDrugUserFeeAct
E:\FR\FM\15AUN1.SGM
15AUN1
38696
Federal Register / Vol. 82, No. 156 / Tuesday, August 15, 2017 / Notices
ADUFA/ucm042896.htm or in this
docket at https://www.regulations.gov.
Animal
drug sponsors are required to report
annually to FDA the amount of
antimicrobials sold or distributed for
use in food-producing animals and
provide species-specific estimates of the
percentage of their drug product sales
for use in any of the four major foodproducing species (cattle, swine,
chickens, and turkeys) identified on the
approved product label (21 CFR
514.87(c)). FDA is announcing the
availability of a proposed method for
using a biomass denominator to adjust
these sales data. The proposed method
will provide estimates of annual
antimicrobial drug sales adjusted for the
size of the animal population (the
animal biomass of each such species)
potentially being treated with those
drugs. The adjusted estimates will
provide insight into broad shifts in the
amount of antimicrobials sold for use in
food-producing animals and give the
Agency a more nuanced view of why
sales increase or decrease over time in
a manner that is specific to U.S. animal
production. Such analysis will also
support our ongoing efforts to encourage
the judicious use of antimicrobials in
food-producing animals to help ensure
the continued availability of safe and
effective antimicrobials for animals and
humans.
Application of a biomass denominator
to normalize antimicrobial sales data
has been used internationally. In
developing this proposal for applying a
biomass denominator to antimicrobial
sales data in the United States, FDA has
considered methods being utilized and
discussed in other countries. FDA’s
intent in publishing the proposed
method is to initiate discussion with
stakeholders on the biomass correction
method FDA is considering, and to seek
comment on the methodology and the
utility of this type of data analysis.
mstockstill on DSK30JT082PROD with NOTICES
SUPPLEMENTARY INFORMATION:
Dated: August 10, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
[FR Doc. 2017–17206 Filed 8–14–17; 8:45 am]
BILLING CODE 4164–01–P
National Institutes of Health
National Institute on Aging; Notice of
Closed Meetings
Sujaya Dessai, Center for Veterinary
Medicine (HFV–212), Food and Drug
Administration, 7519 Standish Pl.,
Rockville, MD 20855, 240–402–5671,
sujaya.dessai@fda.hhs.gov.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
FOR FURTHER INFORMATION CONTACT:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institute of Environmental
Health Sciences; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Alzheimer’s
Disease Drug Development.
Date: September 15, 2017.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway, Suite 2W200, 7201 Wisconsin Ave.,
Bethesda, MD 20892 (Telephone Conference
Call).
Contact Person: Alexander Parsadanian,
Ph.D., Scientific Review Officer, National
Institute on Aging, Gateway Building 2C/212,
7201 Wisconsin Avenue, Bethesda, MD
20892, 301–496–9666, parsadaniana@
nia.nih.gov.
Name of Committee: National Institute on
Aging Special Emphasis Panel; AD
Sequencing Project Data Analysis.
Date: September 20, 2017.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway, Suite 2W200, 7201 Wisconsin Ave.,
Bethesda, MD 20892 (Telephone Conference
Call).
Contact Person: Alexander Parsadanian,
Ph.D., Scientific Review Officer, National
Institute on Aging, Gateway Building 2C/212,
7201 Wisconsin Avenue, Bethesda, MD
20892, 301–496–9666, parsadaniana@
nia.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: August 8, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–17155 Filed 8–14–17; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
21:43 Aug 14, 2017
Jkt 241001
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
Name of Committee: Environmental Health
Sciences Review Committee.
Date: August 29–30, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Sheraton Imperial Hotel and
Convention Center, 4700 Emperor Boulevard,
Durham, NC 27703.
Contact Person: Linda K. Bass, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research and
Training, Nat’l Institute of Environmental
Health Sciences, P.O. Box 12233, MD EC–30,
Research Triangle Park, NC 27709, (919) 541–
1307.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of
Environmental Health Sciences Special
Emphasis Panel; 1 P30 Core Center Conflict
Review.
Date: August 30, 2017.
Time: 2:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Sheraton Imperial Hotel and
Convention Center, 4700 Emperor Boulevard,
Durham, NC 27703.
Contact Person: Leroy Worth, Ph.D.,
Scientific Review Officer Scientific Review
Branch, Division of Extramural Research and
Training, Nat. Institute of Environmental
Health Sciences, P.O. Box 12233, MD EC–30/
Room 3171, Research Triangle Park, NC
27709, 919/541–0670, worth@niehs.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.115, Biometry and Risk
Estimation—Health Risks from
Environmental Exposures; 93.142, NIEHS
Hazardous Waste Worker Health and Safety
E:\FR\FM\15AUN1.SGM
15AUN1
Agencies
[Federal Register Volume 82, Number 156 (Tuesday, August 15, 2017)]
[Notices]
[Pages 38695-38696]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-17206]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2017-N-1197]
The Food and Drug Administration's Proposed Method for Adjusting
Data on Antimicrobials Sold or Distributed for Use in Food-Producing
Animals Using a Biomass Denominator; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
the availability for public comment of a proposed method for applying a
food animal biomass denominator to annual data on antimicrobials sold
and distributed for use in food animals in the United States. This
method will allow us to obtain a corrected estimate of antimicrobial
drug sales relative to the animal population potentially being treated
with those drugs, thereby lending further context to the antimicrobial
sales data we are collecting and analyzing.
DATES: Submit either electronic or written comments on the proposed
method by November 13, 2017.
ADDRESSES: You may submit comments as follows. Please note that late,
untimely filed comments will not be considered. Electronic comments
must be submitted on or before November 13, 2017. The https://www.regulations.gov electronic filing system will accept comments until
midnight Eastern Time at the end of November 13, 2017. Comments
received by mail/hand delivery/courier (for written/paper submissions)
will be considered timely if they are postmarked or the delivery
service acceptance receipt is on or before that date.
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2017-N-1197 for ``FDA's Proposed Method for Adjusting Data on
Antimicrobials Sold or Distributed for Use in Food-Producing Animals
Using a Biomass Denominator.'' Received comments, those filed in a
timely manner (see ADDRESSES), will be placed in the docket and, except
for those submitted as ``Confidential Submissions,'' publicly viewable
at https://www.regulations.gov or at the Dockets Management Staff
between 9 a.m. and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.
Submit written requests for single copies of the proposed method to
the Policy and Regulations Staff (HFV-6), Center for Veterinary
Medicine, Food and Drug Administration, 7519 Standish Pl., Rockville,
MD 20855. Send one self-addressed adhesive label to assist that office
in processing your requests. Persons with access to the Internet may
obtain the proposed method at either https://www.fda.gov/ForIndustry/UserFees/AnimalDrugUserFeeAct
[[Page 38696]]
ADUFA/ucm042896.htm or in this docket at https://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT: Sujaya Dessai, Center for Veterinary
Medicine (HFV-212), Food and Drug Administration, 7519 Standish Pl.,
Rockville, MD 20855, 240-402-5671, sujaya.dessai@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Animal drug sponsors are required to report
annually to FDA the amount of antimicrobials sold or distributed for
use in food-producing animals and provide species-specific estimates of
the percentage of their drug product sales for use in any of the four
major food-producing species (cattle, swine, chickens, and turkeys)
identified on the approved product label (21 CFR 514.87(c)). FDA is
announcing the availability of a proposed method for using a biomass
denominator to adjust these sales data. The proposed method will
provide estimates of annual antimicrobial drug sales adjusted for the
size of the animal population (the animal biomass of each such species)
potentially being treated with those drugs. The adjusted estimates will
provide insight into broad shifts in the amount of antimicrobials sold
for use in food-producing animals and give the Agency a more nuanced
view of why sales increase or decrease over time in a manner that is
specific to U.S. animal production. Such analysis will also support our
ongoing efforts to encourage the judicious use of antimicrobials in
food-producing animals to help ensure the continued availability of
safe and effective antimicrobials for animals and humans.
Application of a biomass denominator to normalize antimicrobial
sales data has been used internationally. In developing this proposal
for applying a biomass denominator to antimicrobial sales data in the
United States, FDA has considered methods being utilized and discussed
in other countries. FDA's intent in publishing the proposed method is
to initiate discussion with stakeholders on the biomass correction
method FDA is considering, and to seek comment on the methodology and
the utility of this type of data analysis.
Dated: August 10, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.
[FR Doc. 2017-17206 Filed 8-14-17; 8:45 am]
BILLING CODE 4164-01-P